GE Stock Surges 129.4% to 159th in Market Rankings as FDA Approves Expanded Use of Vizamyl for Alzheimer's Detection

On June 24, 2025, GE's trading volume reached $497 million, marking a 129.4% increase from the previous day, placing it 159th in the day's stock market rankings. GE HealthCare (GEHC) saw a 1.12% increase.

The U.S. Food and Drug Administration (FDA) has approved expanded indications for GE HealthCare's Vizamyl PET imaging agent, which is used for the detection of beta-amyloid. This approval allows for more precise care for Alzheimer's patients by enabling quantitative analysis of Vizamyl scans. The updated label supports continuous measurement of plaque density via software like GE's MIM Neuro, moving beyond subjective visual assessments and aligning with emerging clinical guidelines that prioritize objective metrics for diagnosing Alzheimer's.

Additionally, the expanded use of Vizamyl now includes monitoring anti-amyloid therapies, allowing for personalized adjustments to treatments. This dual role as both a diagnostic tool and a therapy monitor creates a recurring revenue stream as patients require longitudinal imaging. The update also permits Vizamyl to predict dementia progression in mild cognitive impairment (MCI) patients and streamline Alzheimer's diagnosis, addressing critical gaps in current practices where delayed or misdiagnoses are common.

Vizamyl faces competition from Eli Lilly's Amyvid and Life Molecular Imaging's Neuraceq. However, GE's advancements create strategic separation with its quantitative edge, therapeutic synergy, and global infrastructure. The Alzheimer's diagnostics market is projected to grow at a CAGR of ~8% through 2030, driven by early detection initiatives and regulatory approvals for disease-modifying therapies. Vizamyl's expanded label directly aligns with these trends, but risks such as pricing and reimbursement, competitor innovations, and regulatory hurdles persist.